

# PHOS2

Phosphate (Inorganic) ver.2

cobas®

## Order information

REF	CONTENT	Analyzer(s) on which <b>cobas c</b> pack(s) can be used
08058610190	Phosphate (Inorganic) ver.2 (750 tests)	System-ID 2099 001 <b>cobas c 303, cobas c 503</b>
Materials required (but not provided):		
10759350190	Calibrator f.a.s. (12 x 3 mL)	Code 20401
05117003190	PreciControl ClinChem Multi 1 (20 x 5 mL)	Code 20391
05947626190	PreciControl ClinChem Multi 1 (4 x 5 mL)	Code 20391
05117216190	PreciControl ClinChem Multi 2 (20 x 5 mL)	Code 20392
05947774190	PreciControl ClinChem Multi 2 (4 x 5 mL)	Code 20392
08063494190	Diluent NaCl 9 % (123 mL)	System-ID 2906 001

## English

### System information

**PHOS2:** ACN 20990 (Serum/plasma)

**PHOS2U:** ACN 20991 (Urine)

### Intended use

In vitro test for the quantitative determination of phosphorus in human serum, plasma and urine on Roche/Hitachi **cobas c** systems.

### Summary<sup>1,2,3,4,5</sup>

88 % of the phosphorus contained in the body is localized in bone in the form of calcium phosphate as the apatite  $\text{Ca}^{2+}[\text{Ca}_3(\text{PO}_4)_2]_3^{2-}$ . The remainder is involved in intermediary carbohydrate metabolism and in physiologically important substances such as phospholipids, nucleic acids and ATP. Phosphorus occurs in blood in the form of inorganic phosphate and in organically bound phosphoric acid. The small amount of extracellular organic phosphorus is found almost exclusively in the form of phospholipids.


The ratio of phosphate to calcium in the blood is approximately 6:10. An increase in the level of phosphorus causes a decrease in the calcium level. The mechanism is influenced by interactions between parathormone and vitamin D. Hypoparathyroidism, vitamin D intoxication and renal failure with decreased glomerular phosphate filtration give rise to hyperphosphatemia. Hypophosphatemia occurs in rickets, hyperparathyroidism and Fanconi's syndrome.

The preferred method for the determination of inorganic phosphorus is based on the formation of ammonium phosphomolybdate with subsequent reduction to molybdenum blue. Reagent stability problems often occur with this method. The method presented here is based on the reaction of phosphate with ammonium molybdate to form ammonium phosphomolybdate without reduction. The addition of an accelerator gives rise to a more rapid rate of reaction and the application of sample blanking yields more precise results.

### Test principle<sup>5</sup>

Molybdate UV.

Inorganic phosphate forms an ammonium phosphomolybdate complex having the formula  $(\text{NH}_4)_3[\text{PO}_4(\text{MoO}_3)_{12}]$  with ammonium molybdate in the presence of sulfuric acid.



The concentration of phosphomolybdate formed is directly proportional to the inorganic phosphate concentration and is measured photometrically.

### Reagents - working solutions

**R1** Sulfuric acid: 0.36 mol/L; detergent

**R3** Ammonium molybdate: 3.5 mmol/L; sulfuric acid: 0.36 mol/L; sodium chloride: 150 mmol/L

R1 is in position B and R3 is in position C.

### Precautions and warnings

For in vitro diagnostic use for health care professionals. Exercise the normal precautions required for handling all laboratory reagents.

Infectious or microbial waste:

Warning: handle waste as potentially biohazardous material. Dispose of waste according to accepted laboratory instructions and procedures.

Environmental hazards:

Apply all relevant local disposal regulations to determine the safe disposal.

Safety data sheet available for professional user on request.

This kit contains components classified as follows in accordance with the Regulation (EC) No. 1272/2008:



### Warning

H290 May be corrosive to metals.

H412 Harmful to aquatic life with long lasting effects.

### Prevention:

P234 Keep only in original packaging.

P273 Avoid release to the environment.

### Response:

P390 Absorb spillage to prevent material damage.

### Disposal:

P501 Dispose of contents/container to an approved waste disposal plant.

Product safety labeling follows EU GHS guidance.

Contact phone: all countries: +49-621-7590

### Reagent handling

Ready for use

### Storage and stability

Shelf life at 2-8 °C:

See expiration date on **cobas c** pack label.

On-board in use and refrigerated on the analyzer: 26 weeks

### Specimen collection and preparation

For specimen collection and preparation only use suitable tubes or collection containers.

Only the specimens listed below were tested and found acceptable.

Serum

Plasma: Li-heparin and K<sub>2</sub>-EDTA plasma

The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. When processing samples in primary

# PHOS2

## Phosphate (Inorganic) ver.2



tubes (sample collection systems), follow the instructions of the tube manufacturer.

### Urine

Collect in detergent-free containers. Acidify with hydrochloric acid after collection (pH < 3).<sup>6,7</sup>

<i>Stability in serum/plasma:</i> <sup>8</sup>	24 hours at 15-25 °C
	4 days at 2-8 °C
	1 year at (-15)-(-25) °C
<i>Stability in urine:</i> <sup>6,7</sup>	6 months at 2-8 °C (when acidified)
24-hour urine:	Store cooled during collection.

Centrifuge samples containing precipitates before performing the assay.

If stabilizers are added to the sample, the sample index feature must not be used.

See the limitations and interferences section for details about possible sample interferences.

Sample stability claims were established by experimental data by the manufacturer or based on reference literature and only for the temperatures/time frames as stated in the method sheet. It is the responsibility of the individual laboratory to use all available references and/or its own studies to determine specific stability criteria for its laboratory.

### Materials provided

See "Reagents – working solutions" section for reagents.

### Materials required (but not provided)

See "Order information" section

General laboratory equipment

### Assay

For optimum performance of the assay follow the directions given in this document for the analyzer concerned. Refer to the appropriate operator's manual for analyzer-specific assay instructions.

The performance of applications not validated by Roche is not warranted and must be defined by the user.

### Application for serum and plasma

#### Test definition

Reporting time	10 min		
Wavelength (sub/main)	700/340 nm		
Reagent pipetting		Diluent (H <sub>2</sub> O)	
R1	58 µL	18 µL	
R3	24 µL	–	

Sample volumes	Sample	Sample dilution	
		Sample	Diluent (NaCl)
Normal	1.6 µL	–	–
Decreased	3.2 µL	20 µL	60 µL
Increased	1.6 µL	–	–

### Application for urine

#### Test definition

Reporting time	10 min		
Wavelength (sub/main)	700/340 nm		
Reagent pipetting		Diluent (H <sub>2</sub> O)	
R1	58 µL	18 µL	
R3	24 µL	–	

Sample volumes	Sample	Sample dilution	
----------------	--------	-----------------	--

		Sample	Diluent (NaCl)
Normal	1.6 µL	10 µL	100 µL
Decreased	1.6 µL	5 µL	105 µL
Increased	1.6 µL	10 µL	100 µL

For further information about the assay test definitions refer to the application parameters setting screen of the corresponding analyzer and assay.

### Calibration

#### Application for serum/plasma (ACN 20990)

Calibrators	S1: H <sub>2</sub> O
	S2: C.f.a.s.
Calibration mode	Linear
Calibration frequency	Automatic full calibration
	- after reagent lot change
	Full calibration
	- as required following quality control procedures

#### Application for urine (ACN 20991)

Transfer of calibration from serum/plasma application (ACN 20990)

Calibration interval may be extended based on acceptable verification of calibration by the laboratory.

Traceability: This method has been standardized against NERL primary reference material.

### Quality control

For quality control, use control materials as listed in the "Order information" section. In addition, other suitable control material can be used.

Serum/plasma:	PreciControl ClinChem Multi 1, PreciControl ClinChem Multi 2
Urine:	Quantitative urine controls are recommended for routine quality control.

The control intervals and limits should be adapted to each laboratory's individual requirements. It is recommended to perform quality control always after lot calibration and subsequently at least every 26 weeks. Values obtained should fall within the defined limits. Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.

Follow the applicable government regulations and local guidelines for quality control.

### Calculation

**cobas c** systems automatically calculate the analyte concentration of each sample in the unit mmol/L (mg/dL, mg/L).

Conversion factors:	mmol/L x 3.10 = mg/dL
	mmol/L x 31 = mg/L

### Limitations - interference<sup>6</sup>

Criterion: Recovery within ± 10 % of initial value at a phosphate concentration of 0.87 mmol/L in serum and 13 mmol/L in urine.

#### Serum/plasma

Icterus:<sup>9</sup> No significant interference up to an I index of 40 for conjugated and 60 for unconjugated bilirubin (approximate conjugated bilirubin concentration: 684 µmol/L or 40 mg/dL and approximate unconjugated bilirubin concentration: 1026 µmol/L or 60 mg/dL).

Hemolysis:<sup>9</sup> No significant interference up to an H index of 300 (approximate hemoglobin concentration: 186 µmol/L or 300 mg/dL).

Note: This interference results from inorganic phosphates produced by the action of phosphatases on organic phosphates, both of which are released from the red cells upon hemolysis.

Lipemia (Intralipid):<sup>9</sup> No significant interference up to an L index of 1250. There is poor correlation between the L index (corresponds to turbidity) and triglycerides concentration.

# PHOS2

## Phosphate (Inorganic) ver.2



Drugs: No interference was found at therapeutic concentrations using common drug panels.<sup>10,11</sup>

Exception: Phospholipids contained in liposomal drug formulations (eg AmBisome) may be hydrolyzed in the test due to the acidic reaction pH and thus lead to elevated phosphate results.<sup>12</sup>

In very rare cases, gammopathy, in particular type IgM (Waldenström's macroglobulinemia), may cause unreliable results.<sup>13</sup>

### Urine

Hemolysis: No significant interference up to an H index of 750 (approximate hemoglobin concentration: 466 µmol/L or 750 mg/dL).

Urea: No significant interference from urea up to a concentration of 1500 mmol/L (9009 mg/dL).

Drugs: No interference was found at therapeutic concentrations using common drug panels.<sup>11</sup>

For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination and other findings.

### ACTION REQUIRED

**Special Wash Programming:** The use of special wash steps is mandatory when certain test combinations are run together on **cobas c** systems. All special wash programming necessary for avoiding carry-over is available via the **cobas** link. The latest version of the carry-over evasion list can be found with the NaOHD/SMS/SCCS Method Sheet for information. For further instructions refer to the operator's manual.

### Limits and ranges

#### Measuring range

##### Serum/plasma

0.10-6.46 mmol/L (0.31-20.0 mg/dL)

Determine samples having higher concentrations via the rerun function. Dilution of samples via the rerun function is a 1:2 dilution. Results from samples diluted using the rerun function are automatically multiplied by a factor of 2.

##### Urine

1.1-92 mmol/L (3.4-285 mg/dL)

Determine samples having higher concentrations via the rerun function. Dilution of samples via the rerun function is a 1:2 dilution. Results from samples diluted using the rerun function are automatically multiplied by a factor of 2.

### Lower limits of measurement

#### Limit of Blank, Limit of Detection and Limit of Quantitation

##### Serum/plasma

Limit of Blank = 0.1 mmol/L (0.31 mg/dL)

Limit of Detection = 0.1 mmol/L (0.31 mg/dL)

Limit of Quantitation = 0.1 mmol/L (0.31 mg/dL)

##### Urine

Limit of Blank = 1.1 mmol/L (3.4 mg/dL)

Limit of Detection = 1.1 mmol/L (3.4 mg/dL)

Limit of Quantitation = 1.1 mmol/L (3.4 mg/dL)

The Limit of Blank, Limit of Detection and Limit of Quantitation were determined in accordance with the CLSI (Clinical and Laboratory Standards Institute) EP17-A2 requirements.

The Limit of Blank is the 95<sup>th</sup> percentile value from  $n \geq 60$  measurements of analyte-free samples over several independent series. The Limit of Blank corresponds to the concentration below which analyte-free samples are found with a probability of 95 %.

The Limit of Detection is determined based on the Limit of Blank and the standard deviation of low concentration samples.

The Limit of Detection corresponds to the lowest analyte concentration which can be detected (value above the Limit of Blank with a probability of 95 %).

The Limit of Quantitation is the lowest analyte concentration that can be reproducibly measured with a total error of 30 %. It has been determined using low concentration phosphate samples.

### Expected values

#### Serum/plasma

##### mmol/L

Adults:<sup>14</sup>

0.81-1.45 mmol/L

Children:<sup>15</sup>

Age	Male	Female
1-30 d	1.25-2.25	1.40-2.50
1-12 m	1.15-2.15	1.20-2.10
1-3 y	1.00-1.95	1.10-1.95
4-6 y	1.05-1.80	1.05-1.80
7-9 y	0.95-1.75	1.00-1.80
10-12 y	1.05-1.85	1.05-1.70
13-15 y	0.95-1.65	0.90-1.55
16-18 y	0.85-1.60	0.80-1.55

##### mg/dL

Adults:<sup>14</sup>

2.5-4.5 mg/dL

Children:<sup>15</sup>

Age	Male	Female
1-30 d	3.9-6.9	4.3-7.7
1-12 m	3.5-6.6	3.7-6.5
1-3 y	3.1-6.0	3.4-6.0
4-6 y	3.3-5.6	3.2-5.5
7-9 y	3.0-5.4	3.1-5.5
10-12 y	3.2-5.7	3.3-5.3
13-15 y	2.9-5.1	2.8-4.8
16-18 y	2.7-4.9	2.5-4.8

##### Urine

#### mmol/L, mmol/d

1st morning urine<sup>16</sup> 13-44 mmol/L

24-hour urine<sup>6</sup> 13-42 mmol/d

#### mg/dL, g/d

1st morning urine<sup>16</sup> 40-136 mg/dL\*

24-hour urine<sup>6</sup> 0.4-1.3 g/d

\* calculated by unit conversion factor

Each laboratory should investigate the transferability of the expected values to its own patient population and if necessary determine its own reference ranges.

### Specific performance data

Representative performance data on the analyzers are given below. These data represent the performance of the analytical procedure itself.

Results obtained in individual laboratories may differ due to heterogeneous sample materials, aging of analyzer components and mixture of reagents running on the analyzer.

### Precision

Precision was determined using human samples and controls in accordance with the CLSI (Clinical and Laboratory Standards Institute) EP05-A3 requirements with repeatability ( $n = 84$ ) and intermediate precision (2 aliquots per run, 2 runs per day, 21 days). Results for repeatability and intermediate precision were obtained on the **cobas c** 503 analyzer.

#### Serum/plasma

Repeatability	Mean mmol/L	SD mmol/L	CV %
---------------	----------------	--------------	---------

# PHOS2

Phosphate (Inorganic) ver.2



PCCC1 <sup>a)</sup>	1.34	0.00636	0.5
PCCC2 <sup>b)</sup>	2.35	0.00939	0.4
Human serum 1	0.256	0.00301	1.2
Human serum 2	1.11	0.00546	0.5
Human serum 3	1.68	0.00732	0.4
Human serum 4	3.75	0.0150	0.4
Human serum 5	5.81	0.0176	0.3

<i>Intermediate precision</i>	<i>Mean</i>	<i>SD</i>	<i>CV</i>
	<i>mmol/L</i>	<i>mmol/L</i>	<i>%</i>
PCCC1 <sup>a)</sup>	1.34	0.0109	0.8
PCCC2 <sup>b)</sup>	2.39	0.0203	0.9
Human serum 1	0.256	0.00571	2.2
Human serum 2	1.11	0.00788	0.7
Human serum 3	1.71	0.00872	0.5
Human serum 4	3.75	0.0168	0.4
Human serum 5	5.81	0.0236	0.4

a) PreciControl ClinChem Multi 1

b) PreciControl ClinChem Multi 2

## Urine

<i>Repeatability</i>	<i>Mean</i>	<i>SD</i>	<i>CV</i>
	<i>mmol/L</i>	<i>mmol/L</i>	<i>%</i>
Control 1 <sup>c)</sup>	8.38	0.0533	0.6
Control 2 <sup>c)</sup>	16.7	0.0970	0.6
Human urine 1	2.99	0.0380	1.3
Human urine 2	12.1	0.0764	0.6
Human urine 3	27.7	0.164	0.6
Human urine 4	45.2	0.238	0.5
Human urine 5	79.6	0.430	0.5

<i>Intermediate precision</i>	<i>Mean</i>	<i>SD</i>	<i>CV</i>
	<i>mmol/L</i>	<i>mmol/L</i>	<i>%</i>
Control 1 <sup>c)</sup>	8.38	0.0670	0.8
Control 2 <sup>c)</sup>	16.5	0.113	0.7
Human urine 1	3.05	0.0481	1.6
Human urine 2	11.9	0.0957	0.8
Human urine 3	27.7	0.203	0.7
Human urine 4	45.2	0.361	0.8
Human urine 5	79.6	0.587	0.7

c) commercially available control material

The data obtained on **cobas c** 503 analyzer(s) are representative for **cobas c** 303 analyzer(s).

## Method comparison

Inorganic phosphate values for human serum, plasma and urine samples obtained on a **cobas c** 503 analyzer (y) were compared with those determined using the corresponding reagent on a **cobas c** 501 analyzer (x).

### Serum/plasma

Sample size (n) = 75

Passing/Bablok <sup>17</sup>	Linear regression
$y = 1.013x + 0.00734 \text{ mmol/L}$	$y = 1.011x + 0.00582 \text{ mmol/L}$
$r = 0.989$	$r = 1.000$

The sample concentrations were between 0.390 and 5.86 mmol/L.

### Urine

Sample size (n) = 70

Passing/Bablok <sup>17</sup>	Linear regression
$y = 0.986x + 0.0391 \text{ mmol/L}$	$y = 0.993x - 0.0281 \text{ mmol/L}$
$r = 0.996$	$r = 1.000$

The sample concentrations were between 1.21 and 91.8 mmol/L.

Inorganic phosphate values for human serum, plasma and urine samples obtained on a **cobas c** 303 analyzer (y) were compared with those determined using the corresponding reagent on a **cobas c** 501 analyzer (x).

### Serum/plasma

Sample size (n) = 77

Passing/Bablok <sup>17</sup>	Linear regression
$y = 1.015x - 0.009 \text{ mmol/L}$	$y = 1.016x - 0.008 \text{ mmol/L}$
$r = 0.989$	$r = 1.000$

The sample concentrations were between 0.43 and 6.19 mmol/L.

### Urine

Sample size (n) = 73

Passing/Bablok <sup>17</sup>	Linear regression
$y = 1.022x - 0.103 \text{ mmol/L}$	$y = 1.018x - 0.092 \text{ mmol/L}$
$r = 0.981$	$r = 1.000$

The sample concentrations were between 1.59 and 90.0 mmol/L.

## References

- Külpmann WR, Stummvoll HK, Lehmann P. Elektrolyte, Klinik und Labor. Heidelberg: Verlag Klinisches Labor 1993.
- Tietz NW, ed. Fundamentals of Clinical Chemistry Philadelphia, PA: WB Saunders Company 1976;901.
- Fiske CH, Subbarow Y. The colorimetric determination of phosphorus. J Biol Chem 1925;66:375-400.
- Tausky HH, Schoor EA. A microcolorimetric method for the determination of inorganic phosphorus. J Biol Chem 1953;202:675.
- Henry R ed. Clinical Chemistry: Principles and Technics, 2nd ed. New York, NY: Harper & Row 1974;723.
- Tietz NW, ed. Clinical Guide to Laboratory Tests, 4th ed. Philadelphia.WB Saunders Co 2006;852-855.
- NCCLS GP-16A2, Urineanalysis and Collection, Transportation and Preservation of Urine specimens, 2nd edition 2001.
- Use of Anticoagulants in Diagnostic Laboratory Investigations. WHO Publication WHO/DIL/LAB/99.1 Rev. 2: Jan 2002.
- Glick MR, Ryder KW, Jackson SA. Graphical Comparisons of Interferences in Clinical Chemistry Instrumentation. Clin Chem 1986;32:470-475.
- Breuer J. Report on the Symposium "Drug effects in Clinical Chemistry Methods". Eur J Clin Chem Clin Biochem 1996;34:385-386.
- Sonntag O, Scholer A. Drug interference in clinical chemistry: recommendation of drugs and their concentrations to be used in drug interference studies. Ann Clin Biochem 2001;38:376-385.
- Lane JW, Rehak NN, Hortin GL, et al. Pseudohyperphosphatemia associated with high-dose liposomal amphotericin B therapy. Clin Chim Acta 2008;387:145-149.
- Bakker AJ, Mücke M. Gammopathy interference in clinical chemistry assays: mechanisms, detection and prevention. Clin Chem Lab Med 2007;45(9):1240-1243.
- Burtis CA, Ashwood ER, Bruns DE (eds.). Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, 4th ed. St Louis, Missouri; Elsevier Saunders 2006;2290.
- Soldin JS, Brugnara C, Wong EC. Pediatric Reference Intervals. AACC Press. 2005, 5th ed., p. 153.

# PHOS2

Phosphate (Inorganic) ver.2

cobas®




- 16 Krieg M, Gunsser KJ, Steinhagen-Thiessen E, et al. Vergleichende quantitative Analytik klinisch-chemischer Kenngrößen im 24-Stunden-Urin und Morgenurin. J Clin Chem Clin Biochem 1986 Nov;24(11):863-869.
- 17 Bablok W, Passer H, Bender R, et al. A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry, Part III. J Clin Chem Clin Biochem 1988 Nov;26(11):783-790.

A point (period/stop) is always used in this Method Sheet as the decimal separator to mark the border between the integral and the fractional parts of a decimal numeral. Separators for thousands are not used.

Any serious incident that has occurred in relation to the device shall be reported to the manufacturer and the competent authority of the Member State in which the user and/or the patient is established.

## Symbols

Roche Diagnostics uses the following symbols and signs in addition to those listed in the ISO 15223-1 standard (for USA: see [dialog.roche.com](http://dialog.roche.com) for definition of symbols used):

	Contents of kit
	Volume after reconstitution or mixing
	Global Trade Item Number

COBAS, COBAS C and PRECICONTROL are trademarks of Roche.

All other product names and trademarks are the property of their respective owners.

Additions, deletions or changes are indicated by a change bar in the margin.

© 2021, Roche Diagnostics

 0123



Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim  
[www.roche.com](http://www.roche.com)

+800 5505 6606

